Detailed Information

Cited 3 time in webofscience Cited 3 time in scopus
Metadata Downloads

A pilot study of the pharmacokinetics of the modified-release once-daily tacrolimus formulation administered to living-donor liver transplant recipients

Authors
Song G.-W.Lee S.-G.Hwang S.Kim K.-H.Kim W.-J.Sin M.-H.Yoon Y.-I.Tak E.-Y.
Issue Date
Aug-2016
Publisher
Baskent University
Keywords
Drug-level monitoring; Immunosuppression; Prolonged release
Citation
Experimental and Clinical Transplantation, v.14, no.4, pp 412 - 418
Pages
7
Indexed
SCIE
SCOPUS
Journal Title
Experimental and Clinical Transplantation
Volume
14
Number
4
Start Page
412
End Page
418
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/43423
DOI
10.6002/ect.2015.0227
ISSN
1304-0855
2146-8427
Abstract
Objectives: Sustained-release once-daily tacrolimus pharmacokinetics have not yet been characterized in de novo living-donor liver transplant recipients. Here, a 12-week, phase IV, single center, open-label, pros -pective pilot study was conducted to investigate the pharmacokinetics of this formulation in these patients. Materials and Methods: Patients received continuous intravenous infusion of tacrolimus on days 0 to 5 after transplant, which was followed by oral once-daily sustained-release tacrolimus. Two 24-hour pharma -cokinetics profiles were generated for 10 patients on days 6 and 14. Secondary endpoints were minimum (trough level) and maximum whole blood concent -rations, time to maximum concentration, and incidences of acute rejection, patient and graft survival, and adverse events. Results: Mean doses (± standard deviation) of sustained-release tacrolimus on days 6 and 14 were 0.14 ± 0.03 and 0.17 ± 0.04 mg/kg. Levels were within the recommended range throughout the study. When the actual dose was examined, area under the curve from 0 to 24 hours on day 14 was 1.8-fold higher than that on day 6 (423.9 vs 235.7 ng × h/mL). When tacrolimus was normalized to 0.1 mg/kg, area under the curve from 0 to 24 hours on day 14 was 1.5-fold higher than on day 6 (279.3 vs 183.4 ng × h/mL). When we used the actual dose, we found the correlation coefficient between area under the curve from 0 to 24 hours and trough level to be higher on day 6 (r = 0.87) than on day 14 (r = 0.691). No acute rejections, graft losses, patient deaths, or drug-related adverse events were reported. Conclusions: Initial intravenous followed by sustained-release tacrolimus was safe and efficacious in living-donor liver transplant recipients. The mean area under the curve from 0 to 24 hours on day 14 was higher than previously reported; this difference may reflect cautious dosing regimens. © Başkent University 2016 Printed in Turkey. All Rights Reserved.
Files in This Item
There are no files associated with this item.
Appears in
Collections
5. Others > Others(Medicine) > 1. Journal Articles
2. Clinical Science > Department of Hepato-Biliary-Pancreatic Surgery > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Kim, Wan Joon photo

Kim, Wan Joon
Guro Hospital (Department of Hepato-Biliary-Pancreatic Surgery, Guro Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE